Douglas S. Ingram
Net Worth
Last updated:
What is Douglas S. Ingram net worth?
The estimated net worth of Mr. Douglas S. Ingram is at least $17,748,227 as of 3 Nov 2023. He owns shares worth $7,428,227 as insider and has received compensation worth at least $10,320,000 in Sarepta Therapeutics, Inc..
What is the salary of Douglas S. Ingram?
Mr. Douglas S. Ingram salary is $1,290,000 per year as Pres, Chief Executive Officer & Director in Sarepta Therapeutics, Inc..
How old is Douglas S. Ingram?
Mr. Douglas S. Ingram is 62 years old, born in 1963.
What stocks does Douglas S. Ingram currently own?
As insider, Mr. Douglas S. Ingram owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | Pres, Chief Executive Officer & Director | 375,163 | $19.8 | $7,428,227 |
What does Sarepta Therapeutics, Inc. do?
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
